Plain-English translation of NCT06216158 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding (an antibody drug) to improves treatment outcomes for people with multiple myeloma after they've had a stem cell transplant. You'll take one of two treatment plans for 36 months: the medication alone, or this treatment combined with the antibody. The main goal is to see which approach better eliminates remaining cancer cells.
Multiple myeloma is a blood cancer that often comes back even after successful transplant treatment. Researchers want to know if combining two different types of drugs can keep the disease under control longer and prevent relapse.
You likely qualify if…
You likely don't qualify if…
You will take an oral medication daily at home for 36 months in cycles of 29 days each. If you are assigned to the combination arm, you will also receive injections under the skin using a wearable injector system. You'll have regular clinic visits for blood tests and monitoring to track how well the treatment is working and check for side effects. The study ends after three years of maintenance therapy.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
Austria